Literature DB >> 23994891

Cord blood T cells cultured with IL-7 in addition to IL-2 exhibit a higher degree of polyfunctionality and superior proliferation potential.

Sofia Berglund1, Jens Gertow, Isabelle Magalhaes, Jonas Mattsson, Michael Uhlin.   

Abstract

One disadvantage with umbilical cord blood transplantation is that donor lymphocyte infusion (DLI) for treatment of threatening rejection or relapse of underlying malignant disease is not available. We have previously expanded T cells from the cord blood graft in clinical setting using anti-CD3/CD28 paramagnetic beads and interleukin (IL)-2 for possible future DLI. Here we studied the effect of adding clinical-grade IL-7 to the expansion protocol. T cells were positively selected with anti-CD3/CD28 paramagnetic beads and cultured in increasing concentrations of IL-2 with and without IL-7 (20 ng/mL). After 7 days of expansion, the T cells were analyzed for proliferative capacity and investigated with flow cytometry and Luminex to determine phenotype, cytokine production, and responsiveness to mitogenic stimulus. Cultures with IL-7 had significantly greater proliferation rate, higher CD4/CD8 ratio, a lower percentage of central memory T cells (CD45ROCCR7), and a higher percentage of effector memory T cells (CD45ROCCR7). We assessed the production of IL-2, tumor necrosis factor-α, interferon-γ, and CD107a and found a higher percentage of polyfunctional T cells (positive for 3 to 4 factors) in cells cultured with IL-7. The addition of IL-7 gives a proliferative advantage, also in cultures with a lower dose of IL-2. This could prove advantageous in T-cell culture for adoptive transfer to decrease the risk of apoptosis and other negative effects of cytokine deprivation in vivo. Addition of IL-7 also had an effect on the differentiation status of the cord blood-derived T cells. T cells cultured in IL-7 had more polyfunctional traits, possibly increasing the activity of a putative future umbilical cord blood DLI.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23994891     DOI: 10.1097/CJI.0b013e3182a802f6

Source DB:  PubMed          Journal:  J Immunother        ISSN: 1524-9557            Impact factor:   4.456


  7 in total

Review 1.  Engineering cord blood to improve engraftment after cord blood transplant.

Authors:  Rohtesh S Mehta; Hema Dave; Catherine M Bollard; Elizabeth J Shpall
Journal:  Stem Cell Investig       Date:  2017-05-25

Review 2.  Influence of Culture Conditions on Ex Vivo Expansion of T Lymphocytes and Their Function for Therapy: Current Insights and Open Questions.

Authors:  Harish Sudarsanam; Raymund Buhmann; Reinhard Henschler
Journal:  Front Bioeng Biotechnol       Date:  2022-06-29

3.  Activated Allogeneic Donor-derived Marrow-infiltrating Lymphocytes Display Measurable In Vitro Antitumor Activity.

Authors:  Luca Biavati; Kimberly Noonan; Leo Luznik; Ivan Borrello
Journal:  J Immunother       Date:  2019-04       Impact factor: 4.912

4.  Single-Cell Characterization of in vitro Migration and Interaction Dynamics of T Cells Expanded with IL-2 and IL-7.

Authors:  Johanna Tauriainen; Karin Gustafsson; Mårten Göthlin; Jens Gertow; Marcus Buggert; Thomas W Frisk; Annika C Karlsson; Michael Uhlin; Björn Önfelt
Journal:  Front Immunol       Date:  2015-04-28       Impact factor: 7.561

5.  Long-Term Stable Mixed Chimerism after Hematopoietic Stem Cell Transplantation in Patients with Non-Malignant Disease, Shall We Be Tolerant?

Authors:  Arwen Stikvoort; Mikael Sundin; Mehmet Uzunel; Jens Gertow; Berit Sundberg; Marie Schaffer; Jonas Mattsson; Michael Uhlin
Journal:  PLoS One       Date:  2016-05-06       Impact factor: 3.240

6.  Combination Therapy with iRGD-antiCD3 and PD-1 Blockade Enhances Antitumor Potency of Cord Blood-Derived T Cells.

Authors:  Mei Zhu; Hongmei Wang; Shujuan Zhou; Jia Wei; Naiqing Ding; Jie Shao; Lixia Yu; Zhenqing Feng; Baorui Liu
Journal:  Onco Targets Ther       Date:  2021-02-05       Impact factor: 4.147

7.  Optimizing interleukin-2 concentration, seeding density and bead-to-cell ratio of T-cell expansion for adoptive immunotherapy.

Authors:  Sasan Ghaffari; Monireh Torabi-Rahvar; Sajjad Aghayan; Zahra Jabbarpour; Kobra Moradzadeh; Azadeh Omidkhoda; Naser Ahmadbeigi
Journal:  BMC Immunol       Date:  2021-07-03       Impact factor: 3.615

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.